Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on Regulus (RGLS – Research Report). The associated price target is $10.00.
Ram Selvaraju has given his Buy rating due to a combination of factors, primarily driven by the promising interim results from Regulus Therapeutics’ Phase 1b study of farabursen in treating Autosomal Dominant Polycystic Kidney Disease (ADPKD). The study’s fourth cohort demonstrated a significant mechanistic dose response and a reduction in kidney volume growth, indicating potential efficacy of the treatment. Additionally, the safety profile of farabursen was favorable, with the drug being well tolerated among participants.
Furthermore, Regulus has made substantial progress in aligning with the FDA, achieving agreement on key components of the Phase 3 trial design, which includes a pathway for accelerated approval. The positive outcomes from earlier cohorts, particularly the reduction in kidney volume, reinforce the therapeutic potential of farabursen. These developments suggest a high probability of success in meeting efficacy thresholds, supporting the Buy rating and a price target of $10.
Selvaraju covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Vanda, and Anavex Life Sciences. According to TipRanks, Selvaraju has an average return of 3.6% and a 38.08% success rate on recommended stocks.